Danaher Co. (NYSE:DHR) Shares Sold by Adell Harriman & Carpenter Inc.

Adell Harriman & Carpenter Inc. cut its stake in Danaher Co. (NYSE:DHR) by 14.7% in the 4th quarter, HoldingsChannel reports. The fund owned 13,649 shares of the conglomerate’s stock after selling 2,356 shares during the period. Adell Harriman & Carpenter Inc.’s holdings in Danaher were worth $3,158,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. BKM Wealth Management LLC bought a new position in shares of Danaher in the fourth quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. bought a new position in shares of Danaher in the fourth quarter valued at approximately $29,000. OFI Invest Asset Management bought a new stake in Danaher during the third quarter worth approximately $30,000. Rakuten Securities Inc. bought a new stake in Danaher during the fourth quarter worth approximately $36,000. Finally, BluePath Capital Management LLC bought a new stake in Danaher during the third quarter worth approximately $44,000. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Joakim Weidemanis sold 22,433 shares of the firm’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the transaction, the executive vice president now owns 90,412 shares in the company, valued at approximately $22,644,589.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Joakim Weidemanis sold 22,433 shares of the firm’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $250.46, for a total value of $5,618,569.18. Following the transaction, the executive vice president now directly owns 90,412 shares in the company, valued at approximately $22,644,589.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 106,565 shares of company stock worth $26,641,364. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Up 0.1 %

DHR stock traded up $0.24 during midday trading on Monday, reaching $246.82. The company had a trading volume of 1,616,167 shares, compared to its average volume of 2,771,678. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $182.82 billion, a P/E ratio of 42.12, a PEG ratio of 3.80 and a beta of 0.83. The company has a 50 day moving average of $248.87 and a two-hundred day moving average of $231.27.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.36 EPS. On average, equities research analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were issued a dividend of $0.27 per share. The ex-dividend date was Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research reports. Royal Bank of Canada raised their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. KeyCorp upped their price target on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Bank of America upped their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Finally, Citigroup upped their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $269.64.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.